Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2017.10.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regional challenges to optimize the management of patients with severe asthma type 2 inflammation: a Delphi consensus in seven countries.
J Asthma
January 2025
Medical Department, Fundación Neumológica Colombiana, Bogotá, Colombia.
Severe asthma burdens patients and presents clinical management challenges for healthcare professionals. Biologics are crucial interventions for severe type two (T2) patients with high eosinophil counts. We conducted a Delphi consensus in seven developing or typically underrepresented countries to understand expert agreement on managing severe asthma with type two (T2) inflammation.
View Article and Find Full Text PDFExploring the association between socioeconomic inequalities in chronic respiratory disease and all-cause mortality in China: findings from the China Health and Retirement Longitudinal Study.
Front Public Health
January 2025
Department of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xian, China.
Objective: Research on the inequality of chronic respiratory disease (CRD) is limited, and the association between CRD and all-cause mortality is not well-established. Investigating the distribution of CRD and its associated mortality risks is essential for improving CRD conditions and developing targeted intervention measures. This study aimed to explore the relationship between inequalities in CRD and all-cause mortality in China.
View Article and Find Full Text PDFInhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?
Monaldi Arch Chest Dis
January 2025
Department of Community Medicine, K.S. Hegde Medical College, Deralakatte, Karnataka.
The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.
View Article and Find Full Text PDFThe effects of experimental sleep disruption on daytime performance among children with asthma living in urban environments.
Sleep Health
January 2025
Bradley-Hasbro Children's Research Center, Hasbro Children's Hospital, Providence, Rhode Island, USA; Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA; Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Objectives: Children with asthma living in urban environments are at risk for disrupted sleep due to the presence of nocturnal asthma symptoms and urban stressors. Suboptimal sleep can affect children's daily functioning. The current study examined the effects of experimental sleep disruption on daytime performance in children with persistent asthma from urban backgrounds.
View Article and Find Full Text PDFMontelukast Use and the Risk of Neuropsychiatric Adverse Events in Children.
JAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!